Pingora Partners LLC Has $56,000 Position in Gilead Sciences, Inc. $GILD

Pingora Partners LLC cut its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 28.6% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 500 shares of the biopharmaceutical company’s stock after selling 200 shares during the quarter. Pingora Partners LLC’s holdings in Gilead Sciences were worth $56,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of GILD. Price T Rowe Associates Inc. MD lifted its holdings in Gilead Sciences by 314.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company’s stock worth $1,647,484,000 after buying an additional 11,156,382 shares during the period. Nuveen LLC acquired a new position in shares of Gilead Sciences in the 1st quarter valued at about $620,415,000. GAMMA Investing LLC lifted its stake in shares of Gilead Sciences by 13,891.1% in the 1st quarter. GAMMA Investing LLC now owns 2,550,298 shares of the biopharmaceutical company’s stock valued at $285,761,000 after purchasing an additional 2,532,070 shares during the period. Los Angeles Capital Management LLC lifted its stake in shares of Gilead Sciences by 422.6% in the 1st quarter. Los Angeles Capital Management LLC now owns 2,523,036 shares of the biopharmaceutical company’s stock valued at $282,706,000 after purchasing an additional 2,040,261 shares during the period. Finally, Royal Bank of Canada lifted its stake in shares of Gilead Sciences by 30.1% in the 4th quarter. Royal Bank of Canada now owns 8,678,751 shares of the biopharmaceutical company’s stock valued at $801,655,000 after purchasing an additional 2,005,863 shares during the period. 83.67% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on GILD. Daiwa Capital Markets raised Gilead Sciences from a “neutral” rating to an “outperform” rating and set a $128.00 price objective on the stock in a research note on Tuesday, August 19th. Daiwa America raised Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, August 19th. Royal Bank Of Canada boosted their price objective on Gilead Sciences from $96.00 to $98.00 and gave the company a “sector perform” rating in a research note on Friday, August 8th. Truist Financial raised Gilead Sciences from a “hold” rating to a “buy” rating and boosted their price objective for the company from $108.00 to $127.00 in a research note on Friday, August 8th. Finally, UBS Group boosted their target price on Gilead Sciences from $108.00 to $112.00 and gave the company a “neutral” rating in a research report on Friday, August 8th. Three equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $115.39.

Insider Buying and Selling

In other news, CEO Daniel Patrick O’day sold 10,000 shares of the stock in a transaction that occurred on Thursday, August 28th. The stock was sold at an average price of $113.63, for a total value of $1,136,300.00. Following the completion of the sale, the chief executive officer directly owned 595,725 shares of the company’s stock, valued at $67,692,231.75. This represents a 1.65% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Jeffrey Bluestone sold 5,000 shares of the stock in a transaction that occurred on Monday, July 14th. The stock was sold at an average price of $109.74, for a total value of $548,700.00. Following the completion of the sale, the director directly owned 8,920 shares of the company’s stock, valued at approximately $978,880.80. This trade represents a 35.92% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 82,000 shares of company stock valued at $9,371,330. 0.27% of the stock is owned by company insiders.

Gilead Sciences Stock Up 2.0%

GILD stock opened at $115.05 on Friday. The company has a market cap of $142.76 billion, a P/E ratio of 22.92, a price-to-earnings-growth ratio of 0.76 and a beta of 0.36. Gilead Sciences, Inc. has a fifty-two week low of $78.26 and a fifty-two week high of $121.83. The stock’s 50 day simple moving average is $113.59 and its 200 day simple moving average is $109.89. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, topping the consensus estimate of $1.96 by $0.05. The firm had revenue of $7.08 billion during the quarter, compared to the consensus estimate of $6.95 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The company’s quarterly revenue was up 1.4% compared to the same quarter last year. During the same period in the prior year, the business posted $2.01 earnings per share. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, research analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, September 29th. Stockholders of record on Monday, September 15th will be paid a $0.79 dividend. The ex-dividend date of this dividend is Monday, September 15th. This represents a $3.16 annualized dividend and a dividend yield of 2.7%. Gilead Sciences’s dividend payout ratio is 62.95%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.